April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Matrix-Metalloproteinase-9 (MMP-9) - Testing in Dry Eye Syndrome
Author Affiliations & Notes
  • Elisabeth M. Messmer
    Dep. of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Victoria v. Lindenfels
    Dep. of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Alexandra Garbe
    Dep. of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Anselm Kampik
    Dep. of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
  • Footnotes
    Commercial Relationships Elisabeth Messmer, None; Victoria v. Lindenfels, None; Alexandra Garbe, None; Anselm Kampik, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2001. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elisabeth M. Messmer, Victoria v. Lindenfels, Alexandra Garbe, Anselm Kampik; Matrix-Metalloproteinase-9 (MMP-9) - Testing in Dry Eye Syndrome. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2001.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The pathogenesis of Dry Eye Syndrome (DES) is complex. Inflammation seems to play a pivotal role to initiate and maintain the disease process. Multiple inflammatory markers, including MMP-9, have been isolated from the tear film of patients with DES.

Methods: A cohort of 101 probands and patients was evaluated by a subjective symptom questionnaire (ocular surface disease index-OSDI), break up time (BUT), conjunctival and corneal staining, Schirmer test and meibomian gland examination. 54 healthy eyes and 47 eyes fulfilling diagnostic criteria of DES underwent MMP-9 testing of the tear film by a commercially available test (RPSInflammadry™) detecting MMP-9 levels > 40ng/ml.

Results: The MMP-9 tear test showed a significant difference between healthy eyes and eyes with DES (p<0.001). It correlated well with subjective symptoms evaluated by OSDI (p=0.001), BUT < 5 seconds (p<0.013), Schirmer test (p<0.001), conjunctival (p<0.001) as well as corneal staining (p=0.007). Moreover, it correlated with the number of obstructed meibomian ducts (p=0.005) and a pathologic meibomian gland secretion (p=0.001). It was significantly increased in female patients (p<0.001), and patients with autoimmune disease (p=0.005), especially Sjögren-Syndrome (p=0.001, and thyroid disease (p=0.012).

Conclusions: MMP-9-testing in DES is a valuable new diagnostic tool. It correlates well with other dry eye tests. It is especially helpful to identify patients with ocular surface inflammation and autoimmune disease and may facilitate the decision to institute anti-inflammatory treatment in these patients.

Keywords: 486 cornea: tears/tear film/dry eye • 479 cornea: clinical science • 490 cytokines/chemokines  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.